188 related articles for article (PubMed ID: 35437632)
1. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.
Ishido K; Tanabe S; Katada C; Ishibashi Y; Kitahara G; Onoue M; Kubota Y; Furue Y; Wada T; Watanabe A; Kusano C
J Gastrointest Cancer; 2023 Jun; 54(2):485-491. PubMed ID: 35437632
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
4. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
6. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
7. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
Sano A; Sohda M; Nakazawa N; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sakai M; Ogawa H; Shirabe K; Saeki H
BMC Cancer; 2022 Jan; 22(1):22. PubMed ID: 34980017
[TBL] [Abstract][Full Text] [Related]
8. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2955-2960. PubMed ID: 33112554
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.
Yamada T; Hayashi T; Inokuchi Y; Hayashi K; Watanabe H; Komori K; Kano K; Shimoda Y; Fujikawa H; Shiozawa M; Morinaga S; Rino Y; Masuda M; Ogata T; Oshima T
Target Oncol; 2020 Jun; 15(3):317-325. PubMed ID: 32319020
[TBL] [Abstract][Full Text] [Related]
10. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.
Sakai D; Omori T; Fumita S; Fujita J; Kawabata R; Matsuyama J; Yasui H; Hirao M; Kawase T; Kishi K; Taniguchi Y; Miyazaki Y; Kawada J; Satake H; Miura T; Miyake A; Kurokawa Y; Yamasaki M; Yamada T; Satoh T; Eguchi H; Doki Y
Int J Clin Oncol; 2022 Jul; 27(7):1154-1163. PubMed ID: 35489010
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
[TBL] [Abstract][Full Text] [Related]
13. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
[TBL] [Abstract][Full Text] [Related]
14. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.
Katsuya Y; Horinouchi H; Seto T; Umemura S; Hosomi Y; Satouchi M; Nishio M; Kozuki T; Hida T; Sukigara T; Nakamura K; Kuchiba A; Ohe Y
Eur J Cancer; 2019 May; 113():78-86. PubMed ID: 30991261
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer.
Tokumaru S; Koizumi T; Sekino Y; Takeuchi N; Nakata S; Miyagawa Y; Kitazawa M; Muranaka F; Nakamura S; Koyama M; Yamamoto Y; Ehara T; Hondo N; Soejima Y
Oncology; 2021; 99(10):632-640. PubMed ID: 34280933
[TBL] [Abstract][Full Text] [Related]
16. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
[TBL] [Abstract][Full Text] [Related]
17. Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer.
Arigami T; Matsushita D; Okubo K; Yanagita S; Ehi K; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Uenosono Y; Ishigami S; Natsugoe S
Oncology; 2020; 98(9):630-636. PubMed ID: 32428899
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Evaluation of the Efficacy and Adverse Effects of Nivolumab Treatment for Patients with Advanced Gastric Cancer].
Ohta A; Komatsu S; Tsuji R; Tanaka S; Kumano T; Imura K; Shimomura K; Ikeda J; Taniguchi F; Doi T; Yamada S; Tomatsuri N; Yoshida N; Shioaki Y
Gan To Kagaku Ryoho; 2020 Apr; 47(4):725-727. PubMed ID: 32389997
[TBL] [Abstract][Full Text] [Related]
19. Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer.
Sato Y; Yamashita H; Kobayashi Y; Nagaoka K; Hisayoshi T; Kawahara T; Kuroda A; Saito N; Iwata R; Okumura Y; Yagi K; Aiko S; Nomura S; Kakimi K; Seto Y
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068925
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
Matsunaga T; Saito H; Kuroda H; Osaki T; Takahashi S; Iwamoto A; Fukumoto Y; Taniguchi K; Fukuda K; Miyauchi W; Shishido Y; Miyatani K; Fujiwara Y
BMC Cancer; 2022 Apr; 22(1):418. PubMed ID: 35428212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
